ClinicalTrials.gg
RecruitingNCT05702437Updated Jan 12, 2024

Effect of MetS* on Cognitive Performance and Physical Activity (Metabolic Syndrome)

An observational study in Metabolic Syndrome, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Istanbul University - Cerrahpasa · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
82
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Metabolic Syndrome with a site in Turkey — 14 open to participants now, 16 under way, none of them phase 3. Metabolic Syndrome · Turkey.

Planned enrollment
26th of 34
82 · median 102
Started
2023
with 4 others
Observational
34 of 54
13 open now
Primary completion
2024-12
later than 0 of 15 live
Registered
26th of 54
by date

Among the 54 studies in Metabolic Syndrome with a site in Turkey, this one is the 26th largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2023, is one of 34 observational ones, reaches primary completion later than 0 of the 15 other live ones, and was the 26th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

14 of the 54 studies in Metabolic Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Metabolic Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple.

It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases.

The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant.

The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components.

H1:There is a relationship between the MetS and cognitive functions.

Read the detailed description

Voluntary participants who have been diagnosed with MetS and agreed to voluntary health subjects will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into two groups. There will be individuals diagnosed with MetS in the intervention group and healthy individuals who do not have any problems in the control group.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Cognitive Function
  • Physical Performance
  • Adults
  • Chronic Disease
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Men and women who have been diagnosed with MetS according to NCEP-ATP III criteria and healthy individuals who do not have any health problems

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • being between the ages of 18-50
  • Having been educated for at least 5 years and know how to read and write
  • Having been diagnosed with MetS by meeting 3 of the NCEP-ATP III criteria (for participants in the MetS Group)
  • To have a biochemistry test performed within the last 6 months (for the Healthy Group)
  • Not having any MetS components (For the Healthy Group)

Exclusion criteria

Exclusion Criteria:

  • Having any neurological, psychiatric and psychological diseases that may affect cognitive status
  • Taking antipsychiatric medication
  • The presence of any visual-auditory intellectual disability
  • Having undergone bariatric surgery
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
82 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • MetS Group

    it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.

    Other: assessment of cognitive performance

  • Control Group

    it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.

    Other: assessment of cognitive performance

Interventions

  • Otherassessment of cognitive performance

    evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time

    Also known as: assessment of physical performance

06

What researchers measure

Primary outcomes

  1. Evaluation of Metabolic Syndrome-waist circumference

    Waist Circumference measurement will be recorded with a tape measure in the middle between the last palpable rib and the upper edge of the iliac crest.

    Time frame: once, at baseline

  2. Evaluation of Metabolic Syndrome-blood pressure

    "Omron" digital blood pressure monitor will be used to measure systolic and diastolic blood pressure. Participants will be asked to rest for 5 minutes before the measurement.

    Time frame: once, at baseline

  3. Evaluation of Metabolic Syndrome-triglyceride

    Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

    Time frame: once, at baseline

  4. Evaluation of Metabolic Syndrome-HDL-C

    Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

    Time frame: once, at baseline

  5. Evaluation of Metabolic Syndrome-fasting plasma level

    Triglyceride, HDL-C and fasting plasma levels and biochemistry laboratory findings of individuals will be evaluated. Before the analysis, 8-12 hours of fasting is required so that it does not affect the test results.

    Time frame: once, at baseline

  6. Metabolic Syndrome Severity Score

    This scoring creates a z-score by considering factors such as age, race, gender, and metabolic syndrome components values. There is a website that automatically calculates the z-score when these data are entered. (https://metscalc.org/metscalc/)

    Time frame: once, at baseline

  7. Monreal Cognitive Assessment

    This scale consists of parts that evaluate executive functions, attention and concentration, memory, language, abstract thinking, visual-spatial skills, orientation and calculation. The application of MoCA takes about 10 minutes and the total score of the scale is calculated over 30 points. The threshold point value is 21. Scores of 20 or less are considered cognitive dysfunction.

    Time frame: once, at baseline

  8. Stroop Test TBAG Form

    a neuropsychological test that measures focused attention and the speed of information processing

    Time frame: once, at baseline

Secondary outcomes

  1. Mini Mental State Examination

    it is a test consisting of 11 questions that evaluate different cognitive parameters, including recording memory, attention and calculation, recall and language, motor function and perception. The maximum score that can be taken from the test is 30 and there is no time limit. In scoring, 24-30 points are normal, 23 points and below indicate mild cognitive impairment.

    Time frame: once, at baseline

  2. Visual Reaction Test

    the participant sees a red circle appearing on a white screen on the computer at variable time intervals and should press the December key of the computer quickly as soon as he sees the circle.

    Time frame: once, at baseline

  3. International Physical Activity Questionnare Short-Form

    taking into account the last week, the time spent on walking, moderate and vigorous activities is questioned.

    Time frame: once, at baseline

  4. pedometer

    A valid and reliable method for comparing the participants' weekly step counts and determining their physical activity levels

    Time frame: once, at baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786. PubMed 35054972 ↗
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available. PubMed 11368702 ↗
  • Bahchevanov KM, Dzhambov AM, Chompalov KA, Massaldjieva RI, Atanassova PA, Mitkov MD. Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults. Arch Clin Neuropsychol. 2021 May 21;36(4):498-506. doi: 10.1093/arclin/acaa081. PubMed 33067992 ↗
  • Tahmi M, Palta P, Luchsinger JA. Metabolic Syndrome and Cognitive Function. Curr Cardiol Rep. 2021 Oct 19;23(12):180. doi: 10.1007/s11886-021-01615-y. PubMed 34668083 ↗
  • Wichayanrat W, Boripuntakul S, Keawtep P, Worakul P, Sungkarat S. Obesity and Brain Health: The Impact of Metabolic Syndrome and Cardiorespiratory Fitness on Cognitive Performances in Middle-Aged Obese Women. J Prev Alzheimers Dis. 2022;9(4):701-707. doi: 10.14283/jpad.2022.54. PubMed 36281674 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2024, 22 months after the start.

Of 150 non-industry observational studies under Metabolic Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 106. This study's planned 22 months is below that.

Counting every sponsor, half of 161 studies reached it within 42 months; a quarter within 18 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2023
First posted
Jan 27, 2023
StartActual
Feb 20, 2023
Primary completionEst.
Dec 2024
CompletionEst.
May 2025
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05702437
Responsible party
Aysenur Erekdag (Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jan 27, 2023
Start date
Feb 20, 2023
Primary completion
Dec 2024 (estimated)
Completion
May 2025 (estimated)
Last update
Jan 12, 2024

Study contacts

Aysenur Erekdag, MSc
Contact
aysenurerekdag@gmail.com
+905548959013
Ayca Arslanturk, BSc
principal investigator · Bezmialem Vakif University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion